Singer, Donald (2012) siRNA against p22phox. WIPO: World Intellectual Property Organization no.WO/2012/038759 [Online]. Available at: http://patentscope.wipo.int/search/en/detail.jsf?d....

Full text not available from this repository.

Abstract

The invention relates to siRNA against p22phox, compositions comprising the siRNA, methods of treating diseases with the siRNA and cell based systems for studying the effect of p22 phox modulation by siRNA or cells.

Item Type:	Patent
Subjects:	R Medicine > R Medicine (General)
Divisions:	Faculty of Medicine > Warwick Medical School > Metabolic and Vascular Health Faculty of Medicine > Warwick Medical School
Publisher:	WIPO: World Intellectual Property Organization
Place of Publication:	Geneva
Date:	29 March 2012
Identification Number:	WO/2012/038759
Publication Status:	Published
Access rights to Published version:	Open Access
References:	1. Kiefer FN, Neysari S, Humar R, Li W, Munk VC, Battegay EJ. Hypertension and angiogenesis. Curr Pharm Des. 2003;9: 1733- 1744. 2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364. 3. Ushio-Fukai M. Redox signaling in angiogenesis: Role of NADPH oxidase. Cardiovas Res. 2006;71 :226-235. 4. Black MJ, Bertram JF, Johnston CI. Effect of angiotensin-converting enzyme inhibition on myocardial vascularization in the adolescent and adult spontaneously hypertensive rat. J Hyper tens. 2001 ;19:785-794. 5. Piadys P, Sennlaub F, Brault S, Checchin D, Lahaie i, Le NL, Bibeau , Cambonie G, Abran D, Brochu M, Thibault G, Hardy P, Chemtob S, Nuyt AM. Microvascular rarefaction and decreased angiogenesis in rats with fetal programming of hypertension associated with exposure to a low-protein diet in utero. Am J Physiol Regul Integr Comp Physiol. 2005;289:R1580-1588. 6. Hughes AD, Martinez-Perez E, Jabbar AS, Hassan A, Witt NW, Mistry PD, Chapman N, Stanton AV, Beevers G, Pedrinelli R, Parker KH, Thorn SA. Quantification of topological changes in retinal vascular architecture in essential and malignant hypertension. J Hypertens. 2006;24:889-894. 7. Poston L. Influences of maternal nutritional status on vascular function in the offspring. Current drug targets. 2007;8:914-922. 8. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension. 1999;34:655-658. 9. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, Watt GC. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997;99: 1873-1879. 10. Hasan KM, Manyonda IT, Ng FS, Singer DR, Antonios TF. Skin capillary density changes in normal pregnancy and pre-eclampsia. J Hypertens. 2002;20:2439-2443. 11. Antonios TF. Microvascular Rarefaction in Hypertension— Reversal or Over- Correction by Treatment? Am J Hypertens. 2006; 19:484-485. 12. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. C ire Res. 2000;86:494-501. Chen HC, Stone SJ, Zhou P, Buhman KK, Farese RV, Jr. Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue. Diabetes. 2002;51 :3189-3195. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Ore Res. 2002;91 : 1 160-1 167. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation. 2005; 11 1 :2347-2355. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995;96: 1261-1268. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem. 2004;264:85-97. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem. 2002;277: 19952-19960. Ray R, Shah AM. NADPH oxidase and endothelial cell function. Clin Sci (Lond). 2005; 109:217-226. Griendling KK, Sorescu D, Ushio_Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. C ire Res. 2000;86:494-501. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox Is a Critical Component of the Superoxide-generating NADH/NADPH Oxidase System and Regulates Angiotensin Ilinduced Hypertrophy in Vascular Smooth Muscle Cells. J. Biol. Chem. 1996;271 :23317-23321. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277-297. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin Il-mediated Hypertension in the Rat Increases Vascular Superoxide Production via Membrane NADH/NADPH Oxidase Activation . Contribution to Alterations of Vasomotor Tone. J Clin Invest 1996;97: 1916- 1923. ukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Qt, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997;80:45-51. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, Li M, Raggio J, Wellstein A, Chen Y, Welch WJ, Wilcox CS. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension. 2006;47:238-244. Zalba G, San Jose G, Moreno MU, Fortuno A, Diez J. NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid Redox Signal 2005;7: 1327-1336. Kim KI, Na JE, Kang SY, Cho YS, Choi DJ, Kim CH, Kim HS, Oh BH, Choi YH, Kwon IS, Park SC. Impact of NAD(P)H oxidase p22(phox) gene polymorphism on vascular aging in Korean centenarian and nonagenarian. Int J Cardiol. 2007. Hayaishi-Okano R, Yamasaki Y, Kajimoto Y, Sakamoto K, Ohtoshi K, Katakami N, Kawamori D, Miyatsuka T, Hatazaki M, Hazama Y, Hori M. Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. Diabetes Care. 2003;26:458-463. Hayaishi-Okano R, Yamasaki Y, Ohtoshi K, Yasuda T, Katakami N, Hirano T, Yoshino G, Kajimoto Y, Hori M. NAD (P) H oxidase p22 phox C242T polymorphism affects LDL particle size and insulin resistance in Japanese subjects. J Atheroscler Thromb. 2002;9:200-205. He MA, Cheng LX, Jiang CZ, Zeng HS, Wang J, Wang F, Chen Y, Yang M, Tan H, Zheng HY, Hu FB, Wu TC. Associations of polymorphism of P22(phox) C242T, plasma levels of vitamin E, and smoking with coronary heart disease in China. Am heart J 2007; 153 :640 e641 -646. Djordjevic T, Pogrebniak A, BelAiba RS, Bonello S, Wotzlaw C, Acker H, Hess J, Gorlach A. The expression of the NADPH oxidase subunit p22phox is regulated by a redox-sensitive pathway in endothelial cells. Free Rad Biol & Med 2005;38:616-630. Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cel Tis Res 2005;320:437-445. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem. 2003;278: 12094- 12100. Matsumoto T, Claesson- Welsh L. VEGF receptor signal transduction. Sci STKE. 2001;2001 :RE21. de Fougerolles A, Vornlocher H-P, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443-453. Scherer L, Rossi JJ, Weinberg MS. Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther. 14: 1057-1064. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Tr Pharmaco Sci. 2003;24:471-478. Shizukuda Y, Tang S, Yokota R, Ware JA. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. Circ Res. 1999;85:247-256. Zhou X, Murphy FR, Gehdu N, Zhang J, Ireda!e JP, Benyon RC. Engagement of {alpha} v {beta} 3 Integrin Regulates Proliferation and Apoptosis of Hepatic Stellate Cells. J. Biol. Chem. 2004;279:23996-24006. Xu Y, Mirmalek-Sani S, Yang X, Zhang J, Oreffo ROC. Small Interfering RNA (siRNA) against Peroxisome Proliferators-Activated Receptors Gamma (PPARy) Suppresses Adipocyte Differentiation from Human Preadipocytes and Fetal-derived Mesenchymal Cells. Exp Cell Res. 2006;312: 1856-1864. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63. Sarr M, Chataigneau M, Martins S, Schott C, El Bedoui J, Oak MH, Muller B, Chataigneau T, Schini-Kerth VB. Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase. Cardiovasc Res. 2006;71 :794-802. Breviario F, Caveda L, Corada M, Martin-Padura I, Navarro P, Golay J, Introna M, Gulino D, Lampugnani MG, Dejana E. Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. Arterioscler Thromb Vase Biol. 1995; 15: 1229-1239. Caveda L, Martin-Padura I, Navarro P, Breviario F, Corada M, Gulino D, Lampugnani MG, Dejana E. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5 VE-cadherin). J Clin Invest. 1996;98:886-893. Bach TL, Barsigian C, Chalupowicz DG, Busier D, Yaen CH, Grant DS, Martinez J. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res. 1998;238:324-334. Somanath PR, Razorenova OV, Chen J, Byzova TV. Aktl in endothelial cell and angiogenesis. Cell cycle (Georgetown, Tex. 2006;5:512-518. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281 : 1312-1316. Fire A, Xu S, Montgomery MK, ostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391 :806-81 1. Couzin J. BREAKTHROUGH OF THE YEAR: Small RNAs Make Big Splash. Science. 2002;298:2296-2297. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K, Tuschl T. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Anti & Nuc Acid Drug Dev. 2003; 13:83-105. Gandellini P, Folini M, Bandiera R, De Cesare M, Binda M, Veronese S, Daidone MG, Zunino F, Zaffaroni N. Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol. 2007;73: 1703- 1714. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, Burchard J, Linsley PS, Aronin N, Xu Z, Zamore PD. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2006;2:el40. Yunhe Xu S-HM-S, Feng Linjunlong Zhang and Richard O. C. Oreffo. Adipogenic induction using negative small interfering RNA in human fetal mesenchymal stem cells RNA. 2007; 13: 1 179-1183. ei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods. 2006;3:670-676. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS, Khvorova A. 3 [prime] UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Meth. 2006;3: 199-204. ackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W, Khvorova A, Linsley PS. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA. 2006;12: 1 197-1205. Schafer M, Schafer C, Ewald N, Piper HM, Noll T. Role of redox signaling in the autonomous proliferative response of endothelial cells to hypoxia. Circ Res. 2003;92: 1010- 1015. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI, Harrison DG, Sung HJ, Rong Y, Galis ZS. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation. 2004; 109:520-525. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW. Novel role of gp91(phox) -containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91 : 1 160-1 167. Chen J, Somanath PR, Razorenova O, Chen WS, Hay N, Bornstein P, Byzova TV. Aktl regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med. 2005; 1 1 : 1 188-1 196. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Aktl/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem. 2001;276:38349-38352. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson 1, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Aktl gene. Gen & Dev 2001 ; 15:2203-2208. Yuan J, Horvitz HR. A first insight into the molecular mechanisms of apoptosis. Cell. 2004; 116:S53-56, 51 p following S59. Skulachev VP. Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 1998;423:275-280. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem Pharmacol. 1999;57:231-245. Samali A, Nordgren H, Zhivotovsky B, Peterson E, Orrenius S. A comparative study of apoptosis and necrosis in HepG2 cells: oxidant- induced caspase inactivation leads to necrosis. Biochem Biophys Res Commun. 1999;255:6-1 1. Hampton MB, Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett. 1997;414:552-556. Lee YJ, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem. 1999;274: 19792-19798. 69. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, Li M, Raggio J, Wellstein A, Chen Y, Welch WJ, Wilcox CS. RNA Silencing In Vivo Reveals Role of p22phox in Rat Angiotensin Slow Pressor Response. Hypertension 2006;47:238-244. 70. Gulino D, Delachanal E, Concord E, Genoux Y, Morand B, Valiron M-O, Sulpice E, Scaife R, Alemany M, Vernet T. Alteration of Endothelial Cell Monolayer Integrity Triggers Resynthesis of Vascular Endothelium Cadherin. J. Biol. Chem. 1998;273:29786-29793. 71. Nwariaku FE, Liu Z, Zhu X, Nahari D, Ingle C, Wu RF, Gu Y, Sarosi G, Terada LS. NADPH oxidase mediates vascular endothelial cadherin phosphorylation and endothelial dysfunction. Blood 2004;104:3214-3220. 72. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract 2007;4:491-502. 73. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab. 2005;16:293-299. 74. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;1 12:67-75. 75. Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer. 2005;93:425-434. 76. Miyajima A, Kosaka T, Asano T, Asano T, Seta , Kawai T, Hayakawa M. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002;62:4176-4179. 77. Szocs K, Lassegue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, Griendling KK. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vase Biol. 2002;22:21-27. 78. Jacobson GM, Dourron HM, Liu J, Carretero OA, Reddy DJ, Andrzejewski T, Pagano PJ. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res. 2003;92:637-643. 79. Nakamura K, Yamagishi SI, Matsui T, Yoshida T, Takenaka K, Jinnouchi Y, Yoshida Y, Ueda SI, Adachi H, Imaizumi T. Pigment Epithelium-Derived Factor Inhibits Neointimal Hyperplasia after Vascular Injury by Blocking NADPH Oxidase-Mediated Reactive Oxygen Species Generation. Am J Pathol. 2007.
URI:	http://wrap.warwick.ac.uk/id/eprint/49847

Request changes to a record

Actions (login required)

View Item